A liquid biopsy-based assay could detect recurrence prior to imaging in patients with resectable colorectal cancer

A liquid biopsy-based assay could detect recurrence prior to imaging in patients with resectable colorectal cancer

An ultrasensitive circulating tumor DNA (ctDNA)-based liquid biopsy assay detected signs of recurrence prior to imaging and provided prognostic value within one month after surgery in patients with colorectal cancer (CRC), according to interim results from the VICTORI study presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, held April 25–30.

Study Shows ctDNA Liquid Biopsy Detects Colorectal Cancer Recurrence Earlier Than Imaging

VICTORI study shows ultrasensitive ctDNA liquid biopsy detects colorectal cancer recurrence earlier than imaging at AACR Annual Meeting 2025.

AACR 2025: ctDNA Testing Identifies Recurrence Risk Within Weeks of Surgery in Colorectal Cancer

The study found that 4 weeks was the ideal time point to test for cTDNA.